SLC5A2 and coronary artery disorder: Renal protection is a critical component of the therapeutic benefits provided by SGLT2 and GLP-1 RAs, particularly in patients with CAD and Type 2 Diabetes Mellitus (T2DM), where chronic kidney disease (CKD) is highly prevalent and significantly worsens prognosis [25].